Senti Biosciences HoldingsSNTI +3.00%22 PS Ratio is 515.00 as of Jul. 12, 2026, which is 2103% above its 10-year median of 23.38. GuruFocus rates SNTI with a GF Score™ of 22/100. The stock has 7 warning signs investors should review. Among 930 Biotechnology companies, Senti Biosciences Holdings ranks worse than 93.76% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Senti Biosciences Holdings's share price is $1.03.
Senti Biosciences Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Senti Biosciences Holdings's PS Ratio for today is 515.00.
The historical rank and industry rank for Senti Biosciences Holdings's PS Ratio or its related term are showing as below:
SNTI'
s PS Ratio Range Over the Past 10 Years
Min: 5.93 Med: 23.38 Max: 1110
Current: 515
During the past 6 years, Senti Biosciences Holdings's highest PS Ratio was 1110.00. The lowest was 5.93. And the median was 23.38.
SNTI's PS Ratio is ranked worse than 93.76% of 930
companies
in the Biotechnology industry
Industry Median: 9.51
vs SNTI: 515.00
Senti Biosciences Holdings Inc revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue per Share Growth Rate was -90.70% per year.
During the past 6 years, Senti Biosciences Holdings's highest 3-Year average Revenue per Share Growth Rate was 70.50% per year. The lowest was -90.70% per year. And the median was -10.10% per year.
Back to Basics: PS Ratio
Senti Biosciences Holdings (NAS:SNTI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Senti Biosciences Holdings PS Ratio Related Terms
Senti Biosciences Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Senti Biosciences Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Senti Biosciences Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Senti Biosciences Holdings's Share Price of today is $1.03. Senti Biosciences Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Senti Biosciences Holdings (SNTI) has a PS Ratio of 515.00 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Senti Biosciences Holdings and its competitors. This is 2103% above median its historical median of 23.38. Over the past decade, Senti Biosciences Holdings' PS Ratio has ranged from 5.93 to 1,110.00. According to the industry distribution chart, Senti Biosciences Holdings ranks #872 out of 930 companies in the Biotechnology industry, placing it in the top 93.8%.
Is Senti Biosciences Holdings' PS Ratio too high?
Senti Biosciences Holdings' current PS Ratio of 515.00 is 2103% above median its 10-year median of 23.38. Over the past 10 years, this metric has ranged from a low of 5.93 to a high of 1,110.00. The Biotechnology industry median PS Ratio is 9.51. Senti Biosciences Holdings' value of 515.00 is 5315.4% above this industry median. Based on the distribution chart, Senti Biosciences Holdings ranks #872 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' PS Ratio compare to ALGS and CRVO?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #872 out of 930 companies for PS Ratio. This places Senti Biosciences Holdings in the lower half of its industry. The industry median PS Ratio is 9.51. Senti Biosciences Holdings' value of 515.00 is 5315.4% above this benchmark. Historically, Senti Biosciences Holdings' own PS Ratio has ranged from 5.93 to 1,110.00 over the past decade. While the company's 10-year median is 23.38 vs. the industry median of 9.51, Senti Biosciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.51, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senti Biosciences Holdings's current PS Ratio of 515.00 is 5315.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Senti Biosciences Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senti Biosciences Holdings's current PS Ratio is 515.00, which is 2103% above median its own 10-year median of 23.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current PS Ratio of 515.00. The current PS Ratio is 515.00, which is 2103% above median its 10-year median of 23.38 and 5315.4% above the Biotechnology industry median of 9.51. Senti Biosciences Holdings' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current PS Ratio is 515.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
22GF Score
Get the complete analysis for SNTI
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNTI has been successfully added to your 
